RxDoctor Payments Data

Sergio Haynes, PA

Physician Assistant · Burleson, TXNPI 1528391901

Payments from drug & device makers

$8,278in general payments, 2019–2025

Across 513 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$863
  • Novo Nordisk$825
  • AstraZeneca$697
  • Pfizer$655
  • Lilly USA, LLC$538
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$8,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,278 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$35,521
Medicare patients
148
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$40,787
JardianceEmpagliflozin22$22,267
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$21,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,814
EliquisApixaban20$17,738
XareltoRivaroxaban18$16,181
MyrbetriqMirabegron12$12,384
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,006
Humalog Kwikpen U-100Insulin Lispro11$3,064
Varenicline Tartrate15$2,723
SymbicortBudesonide/Formoterol Fumarate11$2,521
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,152
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide27$1,460
Atorvastatin Calcium193$1,447
Rosuvastatin Calcium148$1,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$825$40,78723 claims
Boehringer IngelheimJardiance$297$22,26722 claims
GSKTrelegy Ellipta$863$18,81425 claims
PfizerEliquis$655$17,73820 claims
Johnson & JohnsonXarelto$70$16,18118 claims
Astellas Pharma US IncMyrbetriq$272$12,38412 claims
AstraZenecaBreztri Aerosphere, Symbicort$697$9,52722 claims
AbbVieSynthroid$1,431$71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →